We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

High Court Interprets The Biosimilars Statute — What Now?

Law360, New York (June 14, 2017, 5:02 PM EDT) -- On Monday, the U.S. Supreme Court issued its first interpretation of the biosimilars statute, the Biologics Price Competition and Innovation Act of 2009. The BPCIA, part of Obamacare, introduced an abbreviated pathway for regulatory approval of biosimilars, allowing biosimilars to piggyback on the regulatory data of innovator biologics for their approval. Biosimilars are biologic medicines, grown in living cells, that copy innovator biologics but, due to the complexity of biologic medicines, cannot precisely duplicate them. Along with the regulatory pathway, the BPCIA provides carefully calibrated patent...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.